Changes in Central Arterial Pressure When Comparing ACOG Hypertensive Urgency Protocols

• Status: Withdrawn
• Trial end date: 2017-01-01
• Target enrollment: 0
• Participant gender: Female

Summary

The investigators plan to monitor the central blood pressure in women with severely elevated blood pressures (160/110) in pregnancy in the acute setting. Currently ACOG recommends 3 different options for blood pressure control, however no one has studied how these medications affect the central pressures, only peripheral blood pressure.

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: St. Louis University
• Treatments: Hydralazine; Labetalol; Nifedipine

Criteria

Inclusion Criteria:

• Pregnant women

• Singleton pregnancy

• Severe hypertension as defined by a blood pressure of 160/110 with plans to treat

Exclusion Criteria:

• Multiple pregnancy

• Blood pressures < 160/110, or those whose blood pressures do not require medication for control

• Irregular heart rhythms or arrhythmias

• Peripheral arterial disease, leg artery disease

• Reynaud's phenomena

• Intense cold/hypothermia

• If there is a wound at location of where central arterial cuff would be placed or tonometer for carotid assessment

• Known sensitivity to labetalol, nifedipine, or hydralazine

• Severe tachycardia (>120)

• Greater than 1st degree heart block

• Severe asthma

• Congestive heart failure or heart disease

• Lupus

• Inability to adequately monitor BP

• Inability to monitor fetus (if 23 weeks or above)

• Magnesium started prior to initiation of study